Human pathogen subversion of antigen presentation

Immunological Reviews

Volumn 168, Issue , 1999, Pages 199-215

  Brodsky, Frances M ^a,b   Lem, Lawrence ^a   Solache, Alejandra ^a   Bennett, Elizabeth M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HLA D ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN PRESENTATION; BACTERIUM; CHLAMYDIA TRACHOMATIS; COXIELLA BURNETII; CYTOTOXIC T LYMPHOCYTE; ENDOCYTOSIS; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY GENE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PARASITE; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS;

ANIMALS; ANTIGEN PRESENTATION; BACTERIA; CELL MEMBRANE; EVOLUTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 0033030410     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01294.x     Document Type: Review

References (129)

1. 1. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995;12:181-208.
2. 2. Bodmer JG, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens 1996;49:297-321.
3. h molecule. Nature 1990;348:213-216.
4. 4. Wodarz D, Nowak MA. Evolutionary dynamics of HIV-induced subversion of the immune response. Immunol Rev 1999;168:75-89.
5. - population. Science 1993;260:98-100.
6. 6. Wang H, Eckels DD. Mutations in immunodominant T-cell epitopes derived from the non-structural 3 (NS3) protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T-cell recognition. J Immunol 1999;162:4177-4183.
7. 7. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specifìc adaptive immunity. Annu Rev Immunol 1995;13:251-276.
8. 8. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
9. - T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 1995;63:3302-3308.
10. 10. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-γ-dependent and -independent pathways. J Immunol 1997;158:3344-3352.
11. 11. Igietseme JU, et al. Route of infection that induces a high intensity of γ interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun 1998;66:4030-4035.
12. 12. Ortiz L, et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J Immunol 1996;157:4554-4567.
13. + T cells reactive with Mycobacterium tuberculosis-infected antigen presenting cells. J Exp Med 1998;187:1633-1640.
14. + cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. J Immunol 1999;162:372-379.
15. 15. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P. Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995;181:2085-2095.
16. 16. Krause K-H, Michalak M. Calreticulin. Cell 1997;88:439-443.
17. 17. Bergeron JJ, Brenner MJ, Thomas DY, Williams DB. Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem Sci 1994;19:124-128.
18. 18. Srivastava SP, Fuchs JA, Holtzman JL. The reported cDNA sequence for phospholipase Cα encodes protein disulfide isomerase, isozyme Q-2 and not phospholipase-C. Biochem Biophys Res Commun 1993;193:971-978.
19. 19. Urade R, Nasu M, Moriyama T, Wada K, Kito M. Protein degradation by phosphoinositide-specific phospholipase C-α family from rat liver endoplasmic reticulum. J Biol Chem 1992;267:15152-15159.
20. 20. Oliver JD, van der Wal FJ, Bulleid NJ, High S. Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins. Science 1997;275:86-88.
21. 21. Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996;5:103-114.
22. 22. Hughes EA, Cresswell P. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr Biol 1998;8:709-712.
23. 23. Lehner PJ, Trowsdale J. Antigen presentation: coming out gracefully. Curr Biol 1998;8:R605-R608.
24. 24. Nössner E, Parham P. Species specific difference in chaperone interaction of human and mouse major histocompatibility complex class I molecules. J Exp Med 1995;181:327-337.
25. 25. Suh W-K, Mitchell EK, Yang Y, Peterson PA, Waneck GL, Williams DB. MHC class I molecules form ternary complexes with calnexin and TAP and undergo peptide-regulated interaction with TAP via their extracellular domains. J Exp Med 1996;184:337-348.
26. 26. Carreno BM, Solheim JC, Harris M, Stroynowski I, Connolly JM, Hansen TH. TAP associates with a unique class I conformation, whereas calnexin associates with multiple forms in mouse and man. J Immunol 1995;155:4726-4733.
27. 27. Lindquist JA, Jensen ON, Mann M, Hämmerling GJ. ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J 1998;17:2186-2195.
28. 28. Morrice NA, Powis SJ. A role for the thiol-dependent reductase ERp57 in the assembly of MHC class I molecules. Curr Biol 1998;8:713-716.
29. 2-microglobulin, class I heavy chain conformation, and tapasin in the interactions of class I heavy chain with calreticulin and transporter associated with antigen processing. J Immunol 1997;158:2236-2241.
30. 30. Früh K, Gruhler A, Krishna RM, Schoenhals GJ. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol Rev 1999;168:157-166.
31. 31. Lewis JW, Elliott T. Evidence for successive peptide binding and quality control stages during MHC class I assembly. Curr Biol 1998;8:717-720.
32. 32. Androlewicz MJ, Anderson KS, Cresswell P. Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc Natl Acad Sci USA 1993;90:9130-9134.
33. 33. Higgins CF. ABC transporters: from microorganisms to man. Annn Rev Cell Biol 1992;8:67-113.
34. 34. Townsend A, Trowsdale J. The transporters associated with antigen presentation. Semin Cell Biol 1993;4:53-61.
35. 35. Powis SJ, et al. Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature 1992;357:211-215.
36. 36. Driscoll J, Brown M, Finley D, Monaco JJ. MHC-linked LMP gene produces specifically alter peptidase activities of the proteasome. Nature 1993;365:262-264.
37. 37. Gaczynska M, Rock K, Goldberg A. γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993;365:264-267.
38. 38. Van Kaer L. et al. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994;1:533-541.
39. 39. Fehling HJ, et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994;265:1234-1237.
40. 40. Vinitsky A, Anton LC, Snyder HL, Orlowski M, Bennink JR, Yewdell JW. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors. J Immunol 1997;159:554-564.
41. 41. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998;392:618-622.
42. 42. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence derived peptides. Nature 1992;356:443-446.
43. 43. Henderson RA, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992;255:1264-1266.
44. 44. Braud VM, Allan DSJ, Wilson D, McMichael AJ. TAP-and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1997;8:1-10.
45. 45. Elliott T, Willis A, Cerundolo V, Townsend A. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med 1995;181:1481-1491.
46. 46. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartment. J Exp Med 1994;180:2389-2394.
47. 47. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med 1994;180:1591-1597.
48. 48. Hengel H, et al. Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev 1999;168:167-176.
49. 49. Cosman D, Fanger N, Borges L. Human cytomegalovirus. MHC class I and inhibitory signaling receptors: more questions than answers. Immunol Rev 1999;168:177-185.
50. 50. Farrell HE, Degli-Esposti MA, Davis-Poynter NJ. Cytomegalovirus evasion of natural killer cell responses. Immunol Rev 1999;168:187-197.
51. 51. Collins KL, Baltimore D. HIV's evasion of the cellular immune response. Immunol Rev 1999;168:65-74.
52. 52. Piguet V, Schwartz O, Le Gall S, Trono D. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 1999;168:51-63.
53. 53. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev 1999;168:121-130.
54. 54. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol Rev 1997;159:31-48.
55. 55. Benneu EM, Yewdell JW, Bennink JR, Brodsky FM. Cutting edge: adenovirus has two mechanisms for affecting class I MHC expression. J Immunol 1999;162:5049-5052.
56. 56. Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-253.
57. 57. Wiertz EJHJ, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996;384:432-438.
58. 58. Wiertz EJHJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996;84:169-119.
59. 59. Hughes EA, Hammond C, Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci USA 1997;94:1896-1901.
60. 60. Kerkau T, et al. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997;185:1295-1305.
61. 61. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependem protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen I. Proc Natl Acad Sci USA 1997;94:12616-12621.
62. 62. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-722.
63. 63. Ahn K, et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47. EMBO J 1996;15:3247-3255.
64. 64. Tomazin R, et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 1996;15:3256-3266.
65. 65. Hengel HH, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-632.
66. 66. Ahn K, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997;6:613-621.
67. 67. Früh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995;375:415-418.
68. 68. Burgert H-G, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985;41:987-997.
69. 69. Andersson M, Pääbo S, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985;43:215-222.
70. 70. Jackson M R, Nilsson T, Peterson PA. Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. EMBO J 1990;9:3153-3162.
71. 71. Nilsson T, Jackson M, Peterson PA. Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum. Cell 1989;58:707-718.
72. 72. Cox JH, Yewdell JW, Eisenlohr LC, Johnson PR, Bennink JR. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 1990;247:715-718.
73. 73. Beier DC, Cox JH, Vining DR, Cresswell P, Englehard VH. Association of human class I MHC alleles with the adenovirus E3/19K protein. J Immunol 1994;152:3862-3871.
74. 74. Schmid SL. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu Rev Biochem 1997;66:511-548.
75. 75. Foti M, et al. Nef-mediated clathrin-coated pit formation. J Cell Biol 1997;139:37-47.
76. 76. Bresnahan PA, Yonemoto W, Ferrell S, Williams-Herman D, Geleziunas R, Greene WC. A dileucine motif in HIV-1 nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol 1998;8:1235-1238.
77. 77. Oldridge J, Marsh M. Nef - an adaptor adaptor? Trends Cell Biol 1998;8:302-305.
78. 78. Lu X, Yu H, Liu S-H, Brodsky FM, Peterlin BM. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity 1998;8:647-656.
79. 79. Le Gall S, et al. Nef interacts with the μ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998;8:483-495.
80. 2-microglobulin. Nature 1990;347:770-772.
81. 81. Robbins PA, Maino VC, Warner NL, Brodsky FM. Activated T cells and monocytes have characteristic patterns or class II antigen expression. J Immunol 1988;141:1281-1287.
82. 82. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997;9:89-96.
83. 83. Liu S-H, Marks MS, Brodsky FM. A dominant-negative clathrin mutant differentially affects trafficking of molecules with distinct sorting motifs in the class II major histocompatibility complex (MHC) pathway. J Cell Biol 1998;140:1023-1037.
84. 84. Chapman HA. Endosomal proteolysis and MHC class II function. Curr Opin Immunol 1998;10:93-102.
85. 85. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 1998;161:3282-3291.
86. 86. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. HLA DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996;15:4817-4824.
87. 87. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:78-82.
88. 88. Mellman I, Turley SJ, Steiman RM. Antigen processing for amateurs and professionals. Trends Cell Biol 1998;8:231-237.
89. 89. Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 1998;93:1135-1145.
90. 90. Ramachandra L, et al. Pathogen subversion of cellular immunity. Immunol Rev 1999;168:217-239.
91. 91. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-850.
92. 92. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998;19:362-368.
93. 93. Ernst WA, et al. Molecular interaction of CD1b with lipoglycan antigens. Immunity 1998;8:331-340.
94. 94. Lavoie PM, Thibodeau J, Erard F, Sékaly R-P. Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol Rev 1999;168:257-269.
95. 95. Lee VT, Schneewind O. Type III secretion machines and the pathogenesis of enteric infections caused by Yersinia and Salmonella spp. Immunol Rev 1999;168:241-255.
96. 96. Molinari M, et al. Selective inhibition of Ii-dependent antigen presentation by Helicobacter pylori toxin VacA. J Exp Med 1998;187:135-140.
97. 97. Hackstadt T, Fischer ER, Scidmore MA, Rockey DD, Heinzen RA. Origins and functions of the chlamydial inclusion. Trends Microbiol 1997;5:288-293.
98. 98. Heinzen RA, Scidmore MA, Rockey DD, Hackstadt T. Differential interactions with endocytic and exocytic pathways distinguish parasitophorous vacuoles of Coxiella burnetii and Chlamydia trachomatis. Infect Immun 1996;64:796-809.
99. 99. Clemens DL, Horwitz MA. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is limited. J Exp Med 1995;181:257-270.
100. 100. Sturgill-Koszycki S, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994;263:678-681.
101. 101. Deretic V, Via LE, Fratti RA, Deretic D. Mycobacterial phagosome maturation, rab proteins, and intracellular trafficking. Electrophoresis 1997;18:2542-2547.
102. 102. Hackstadt T, Scidmore MA, Rockey DD. Lipid metabolism in Chlamydia trachomatis-infected cells: directed trafficking of Golgi-derived sphingolipids to the chlamydial inclusion. Proc Natl Acad Sci USA 1995;92:4877-4881.
103. 103. Raoult D, Marrie T. Q fever. Clin Infect Dis 1995;20:489-496.
104. 104. Le HQ, Davidson PT. Reactivation and exogenous reinfection: their relative roles in the pathogenesis of tuberculosis. Curr Clin Top Infect Dis 1996;16:260-276.
105. 105. Rook GA, Stanford JL. The Koch phenomenon and the immunopathology of tuberculosis. Curr Top Microbiol Immunol 1996;215:239-262.
106. 106. Terho P. Chlamydia trachomatis and clinical genital infections: a general review. Infection 1982;10:S5-S9.
107. 107. Centers for Disease Control. Chlamydia trachomatis genital infections-United States 1995. Morbid Mortal Weekly Rep 1997;46:193-198.
108. 108. Ljnnggren G, Anderson DJ. Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells. J Reprod Immunol 1998;38:123-138.
109. 109. Lem L, Riethof DA, Scidmore M, Griffiths G, Hackstadt T, Brodsky FM. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases. J Immunol 1999;162:523-532.
110. 110. Faigle W, et al. Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chédiak-Higashi syndrome. J Cell Biol 1998;141:1121-1134.
111. 111. Rodel J, Groh A, Vogelsang H, Lehmann M, Hartmann M, Straube E. β-Interferon is produced by Chlamydia trachomatis-infected fibroblast-like synoviocytes and inhibits γ-interferon-induced HLA-DR expression. Infect Immun 1998;66:4491-4495.
112. 112. Zhong G, Lu H, Hu H. Effect of Chlamydia trachomatis infection on MHC class II antigen processing and presentation. In: Stephens RS, ed. Chlamydial infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infection; 1998 Jun 21-26; Napa (CA). San Francisco (CA): International Chlamydia Symposium; 1998. p. 379-382.
113. 113. Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991;55:143-190.
114. 114. Pagano RE. A fluorescent derivative of ceramide: physical properties and use in studying the Golgi apparatus of animal cells. Methods Cell Biol 1989;29:75-85.
115. 115. Gercken J, Pryjma J, Ernst M, Flad HD. Defective antigen presentation by Mycobacterium tuberculosis-infected monocytes. Infect Immun 1994;62:3472-3478.
116. 116. Mazzaccaro RJ, et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1996;93:11786-1191.
117. 117. Hmama Z, Gabathuler R, Jefferies WA, de Jong G, Reiner NE. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J Immunol 1998;161:4882-4893.
118. 118. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997;159:635-643.
119. 119. Russell DG. Mycobacterium and Leishmania: stowaways in the endosomal network. Trends Cell Biol 1995;5:125-128.
120. 120. Stenger S, Niazi KR, Modlin RL. Downregulation of GD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J Immunol 1998;161:3582-3588.
121. 121. De Souza Leao S, Lang T, Prina E, Hellio R, Antoine J-C. Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cells. J Cell Sci 1995;108:3219-3231.
122. +-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein. J Biol Chem 1995;270:6830-6837.
123. 123. Tong X, Boll W, Kirchhausen T, Howley PM. Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1. J Virol 1998;72:476-482.
124. 124. Miller DM, et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med 1998;187:675-683.
125. 125. Lewandowski GA, Lo D, Bloom FE. Interference with major histocompatibility complex class II-restricted antigen presentation in the brain by herpes simplex virus type 1 : a possible mechanism of evasion of the immune response. Proc Natl Acad Sci USA 1993;90:2005-2009.
126. 126. Leopardi R, Ilonen J, Mattila L, Salmi AA. Effect of measles virus infection in MHC class II expression and antigen presentation in human monocytes. Cell Immunol 1993;147:388-396.
127. 127. Acha-Orbea H, et al. Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Immunol Rev 1999;168:287-303.
128. 128. Abendroth A, Arvin A. Varicella-zoster virus immune evasion. Immunol Rev 1999;168:143-156.
129. 129. Frazer IH, et al. Pathogen subversion of cellular immunity. Immunol Rev 1999;168:131-142.